We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer.
- Authors
Do Chang Moon; Hee Seung Lee; Yong Il Lee; Moon Jae Chung; Jeong Youp Park; Seung Woo Park; Si Young Song; Jae Bock Chung; Seungmin Bang
- Abstract
Purpose: Erlotinib-gemcitabine combined chemotherapy is considered as the standard treatment for unresectable pancreatic cancer. This study aimed to determine the clinical factors associated with response to this treatment. Materials and Methods: This retrospective study included 180 patients with unresectable pancreatic cancer who received =2 cycles of gemcitabine-erlotinib combination therapy as first-line palliative chemotherapy between 2006 and 2014. "Long-term response" was defined as tumor stabilization after >6 chemotherapy cycles. Results: The median progression-free survival (PFS) and overall survival (OS) were 3.9 and 8.1 months, respectively. On univariate analysis, liver metastasis (p=0.023) was negatively correlated with long-term response. Locally advanced stage (p=0.017), a history of statin treatment (p=0.01), and carcinoembryonic antigen levels <4.5 (p=0.029) had a favorable effect on long-term response. On multivariate analysis, a history of statin treatment was the only independent favorable factor for long-term response (p=0.017). Prognostic factors for OS and PFS were significantly correlated with liver metastasis (p=0.031 and 0.013, respectively). A history of statin treatment was also significantly associated with OS after adjusting for all potential confounders (hazard ratio, 0.48; 95% confidence interval, 0.26-0.92; p=0.026). Conclusion: These results suggest that statins have a favorable effect on "long-term response" to gemcitabine-erlotinib chemotherapy in unresectable pancreatic cancer patients. Statins may have a chemoadjuvant role in stabilizing long-term tumor growth.
- Subjects
PANCREATIC cancer; CANCER patients; PANCREATIC cancer treatment; CANCER chemotherapy; ERLOTINIB; PROGRESSION-free survival; UNIVARIATE analysis; LIVER metastasis; THERAPEUTICS
- Publication
Yonsei Medical Journal, 2016, Vol 57, Issue 5, p1124
- ISSN
0513-5796
- Publication type
Article
- DOI
10.3349/ymj.2016.57.5.1124